Daniel Morillo

Daniel Morillo

Hematology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Medical Sciences
Verified
Journal Article
Open access
PDF file
Alberto Lopez GarciaAlberto Lopez Garcia
Alberto Lopez Garcia
EMEster Macia
Ester Macia
SGSandra Gomez-Talavera
Sandra Gomez-Talavera
ECEva Castillo
Eva Castillo
DMDaniel Morillo
Daniel Morillo
RMRaul Cordoba Mascuñano
Raul Cordoba Mascuñano
Background: Cancer-therapy-related cardiac dysfunction (CTRCD) is a growing concern for public health, with a growing incidence due to improved survival rates of patients with hematological malignancies due to diagnostic and therapeutic advances. The identification of patients at risk for CTRCD is vital to developing preventive strategies. Methods: A single-center retrospective cohort study was conducted between 1 January 2017 and 15 February 2023. Medical records of patients with lymphoma treated with first-line anthracyclines were reviewed. Demographic data, cardiovascular risk factors, biomarkers of myocardial damage, and echocardiographic information were collected. Results: A total of 200 patients were included. The incidence of CTRCD was 17.4% (35/200). Patients with CTRCD were older than those without CTRCD, with a mean age of 65.17 years vs. 56.77 (p = 0.008). Dyslipidemia (DL) (31.4% vs. 13.4% p = 0.017) and previous cardiovascular disease (40% vs. 13.3%; p < 0.001) were more frequent in the group who developed an event. Mean baseline NT-proBNP levels in the subgroup with cardiovascular events were 388.73 kg/L ± 101.02, and they were 251.518 kg/L ± 26.22 in those who did not (p = 0.004). Differences in Troponin I levels were identified during and after treatment without exceeding the laboratory’s upper reference limit. Patients were followed for a median of 51.83 months (0.76–73.49). The presence of a CTCRD event had a negative impact on overall mortality from any cause (HR = 2.23 (95% CI: 1.08–2.93); p = 0.031). Conclusions: Early identification of risk factors is crucial to manage patients at risk for CTRCD.

8 September 2023 in Medicina
Verified
Journal Article
Open access
PDF file
CSCarlos Santonja
Carlos Santonja
DMDaniel Morillo
Daniel Morillo
EPElena Prieto-Pareja
Elena Prieto-Pareja
COCarlos Soto-De Ozaeta
Carlos Soto-De Ozaeta
CCCristina Serrano Castillo
Cristina Serrano Castillo
Socorro María Rodríguez-PinillaSocorro María Rodríguez-Pinilla
Socorro María Rodríguez-Pinilla
Anaplastic large cell lymphoma (ALCL) with leukaemic presentation (either ab initio or along the course of the disease) has been rarely reported. Irrespective of ALK expression in the neoplastic cells, it features a dismal prognosis. We report a rare case of leukaemic, small cell variant ALK-positive ALCL with 9-year survival in a young woman who was treated upfront with corticosteroids and standard chemotherapy, and review thoroughly the previously published cases. Such an unexpected, good outcome hints at the existence of different clinical subgroups in the leukaemic variant of ALK-positive ALCL.

13 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
CSCarlos Santonja
Carlos Santonja
DMDaniel Morillo
Daniel Morillo
EPElena Prieto-Pareja
Elena Prieto-Pareja
COCarlos Soto-De Ozaeta
Carlos Soto-De Ozaeta
CCCristina Serrano Castillo
Cristina Serrano Castillo
Socorro María Rodríguez-PinillaSocorro María Rodríguez-Pinilla
Socorro María Rodríguez-Pinilla
Anaplastic large cell lymphoma (ALCL) with leukemic presentation (either ab initio or along the course of the disease) has been rarely reported. Irrespective of ALK-status in the neoplastic cells, it features a dismal prognosis. We report a case of leukemic, ALK-positive ALCL with 9-year survival in a young woman who was treated upfront with corticosteroids and standard chemotherapy, and review thoroughly the previously published cases. Such an unexpected, good outcome hints at the existence of different clinical subgroups in the leukemic variant of ALCL.

18 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Alberto Lopez GarciaAlberto Lopez Garcia
Alberto Lopez Garcia
STSandra Gomez Talavera
Sandra Gomez Talavera
EMEster Macia
Ester Macia
ECEva Castillo
Eva Castillo
Jose TuñónJose Tuñón
Jose Tuñón
RMRaul Cordoba Mascuñano
Raul Cordoba Mascuñano
Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a growing concern for public health, with a growing incidence due to improved survival rates for patients with hematological malignancies due to diagnostic and therapeutic advances. Identification of patients at risk CTRCD is vital to develop preventive strategies. Methods: A single-center retrospective cohort study was conducted between 1 January 2017 and 15 February 2023. Medical records of patients with lymphoma treated with first-line anthracyclines were reviewed. Demographic data, cardiovascular risk factors, biomarkers of myocardial damage and echocardiographic information were collected. Results: A total of 200 patients were included. The incidence of CTRCD was 17.4 % (35/200). Patients with CTRCD were older than those without CTRCD, with a mean age of 65.17 years vs 56.77 (p = 0.008). Dyslipidemia (DL) (31.4% vs 13.4% p = 0.017) and previous cardiovascular disease (40% vs 13.3%, p< 0.001) were more frequent in the group who developed an event. Mean baseline NT-proBNP levels in the subgroup with cardiovascular events were 388.73 kg /L ± 101.02, and 251.518 kg /L ± 26.22 in those who did not (p = 0.004). Differences in Troponin I levels were identified during and after treatment without exceeding the laboratory’s upper reference limit. Patients were followed for a median of 51.83 months (0.76-73.49). The presence of a CTCRD event had a negative impact on overall mortality from any cause (HR = 2.23 (95% CI 1.08-2.93), p = 0.031). Conclusions: Early identification of risk factors is crucial to manage patients at risk for CTRCD.